Length of Hospital Stay Improved With Dalbavancin Therapy in ABSSSI

Length of stay for ABSSSI hospital admissions were significantly improved after implementing dalbavancin therapy with the ENHANCE ABSSSI trial.

Length of stay (LOS) for acute bacterial skin and skin structure infection (ABSSSI) hospital admissions was significantly improved after implementing dalbavancin-based therapy via the ENHANCE ABSSSI trial (ClinicalTrials.gov identifier: NCT03233438) in eligible patients, according to a poster presented at ID Week 2019, held from October 2 to October 6 in Washington, DC.

Researchers aimed to reduce LOS after ABSSSI hospital admission, using a hospital pathway that leverages long-acting intravenous antibiotic therapy with dalbavancin. Study authors conducted a single-center pre- vs postperiod pragmatic trial at Weill Cornell Medical Center in New York and evaluated care for consecutively enrolled patients with ABSSSI during the observational pre-period. A new ABSSSI pathway was implemented in the postperiod, which contained identification of eligible patients and treatment with dalbavancin.

The study included 48 patients in the pre-period and 43 patients in the postperiod. Patients with potentially fatal infections who required intensive care or multiple antibiotics or had unstable comorbidities were excluded from the study. During a 44-day follow-up period, mean infection-related LOS was reduced in the postperiod (3.2 days vs 4.8 days; P =.003). Results also showed that in the postperiod, work productivity (59.3% vs 18.0%; P =.01) and activity impairment outcomes (18.5% vs 60.2%, P <.001) significantly improved compared with the pre-period. However, quality of life remained similar between the pre- and postperiods.

The complete response to treatment was similar between both periods, whereas a greater number of adverse events occurred in the postperiod compared with the pre-period (48%, and 6%, respectively). Most adverse events were mild in severity and unrelated to the use of antibiotics.

“After implementing the ENHANCE ABSSSI pathway among eligible patients, LOS was significantly reduced by almost 2 days, with potential improvements in work productivity and the ability to complete daily activities,” said study authors.

Related Articles

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.


McCarthy M, Keyloun K, Gillard P, et al. Dalbavancin, a long acting lipoglycopeptide antimicrobial agent, reduces length of stay and improves patient work productivity in a hospital critical pathway for acute bacterial skin and skin structure infections (ABSSSI) – the ENHANCE ABSSSI trial. Presented at: IDWeek 2019; October 2-6, 2019; Washington DC. Poster 456.